Individual Investors

Subscribe to email updates

Subscribe now

Financial Professionals

Subscribe to email updates, or password protected financial professional-only content
email address/username
password

BBH
VanEck Vectors Biotech ETF

  • Fund Description

    VanEck Vectors Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.

  •  
      

    • Fund Ticker

      BBH
    • Exchange

      NASDAQ
    • Commencement

      12/20/2011
    • ETF Structure

      Physical
    • Administrator

      Van Eck Associates
    • Custodian

      Bank of New York Mellon
    • Index Ticker

      MVBBHTR
    • Index Rebalancing

      Quarterly
  •  
    as of 02/27/17

    • 30-Day SEC Yield1

      0.43%
    • Total Net Assets

      $708.7M
    • Number of Holdings

      26
    • Options

      Available
    • Gross Expense Ratio2

      0.40%
    • Net Expense Ratio/TER2

      0.35%
    • Distribution Frequency

      Annual
    • Next Distribution Date

      12/15/2017
  • Key Points

    Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market cap and trading volume
    Industry Leaders 
    Index methodology favors the largest companies in the industry
    Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies allowing for enhanced industry representation
  • Trading Information

    • Fund Ticker

      BBH
    • Index Total Return Ticker

      MVBBHTR
    • NAV

      BBHNV
    • Intraday NAV (IIV)4

      BBHIV
    • Shares Outstanding

      5,846,503
    • Estimated Cash

      BBHEU
    • Total Cash

      BBHTC
    • CUSIP

      92189F726
    • ISIN

      US92189F7261
    Source: Bloomberg
  • Fees and Expenses2

    • Management Fee

      0.35%
    • Other Expenses

      0.05%
    • Gross Expense Ratio

      0.40%
    • Fee Waivers and
      Expense Reimbursement

      -0.05%
    • Net Expense Ratio/TER2

      0.35%
    2 Expenses for BBH are capped contractually at 0.35% until at least February 1, 2018. Cap excludes certain expenses, such as interest.
  • Prices as of 02/27/17

    NAV/
    Last Price
    Volume
    30-Day Avg./
    Last Trading Day
    Daily Change
    NAV/
    Last Price
    YTD Change
    NAV/
    Last Price
    Premium/
    Discount
    Prem/Discount
    Distribution Charts
    NAV &
    Prem/Discount
    History
    NAV
    Chart
    BBH $121.22
    $121.33
    60,050
    97,508
    $2.67 / +2.25%
    $2.83 / +2.39%
    +12.8%
    +12.8%
    $0.11
    0.09%
  • View All IndicesView All ETFsPerformance History: Average Annual Total Returns* (%)

    1 MO3 MOYTD1 YR3 YR5 YR10 YRLIFE
    12/20/11
    BBH (NAV)6.0611.156.0612.335.7522.29--25.98
    BBH (Share Price)5.9511.185.9512.465.7622.32--26.01
    MVBBHTR (Index)6.0811.196.0812.435.9222.43--26.18
    Performance Differential (NAV - Index)-0.02-0.04-0.02-0.10-0.17-0.14---0.20
    Quarter End as of 12/31/16
    1 MO3 MOYTD1 YR3 YR5 YR10 YRLIFE
    12/20/11
    BBH (NAV)-0.99-6.51-15.04-15.046.8724.35--25.01
    BBH (Share Price)-0.85-6.35-15.01-15.016.9124.41--25.06
    MVBBHTR (Index)-0.98-6.52-14.94-14.947.0424.54--25.20
    Performance Differential (NAV - Index)-0.010.01-0.10-0.10-0.17-0.19---0.19
  • Daily HoldingsTop 10 Holdings (%)  as of 01/31/17

    Total Holdings: 26
    Holding Name
    Ticker
    SharesMarket Value
    (US$)
    % of Net
    Assets
    Amgen Inc
    AMGN US
    502,755
    78,771,65312.14
    Celgene Corp
    CELG US
    599,760
    69,662,12410.73
    Gilead Sciences Inc
    GILD US
    960,728
    69,604,74410.72
    Allergan Plc
    AGN US
    273,525
    59,871,8879.22
    Biogen Inc
    BIIB US
    143,175
    39,693,8376.12
    Illumina Inc
    ILMN US
    221,806
    35,511,1415.47
    Incyte Corp
    INCY US
    266,084
    32,252,0424.97
    Vertex Pharmaceuticals Inc
    VRTX US
    359,557
    30,875,1604.76
    Biomarin Pharmaceutical Inc
    BMRN US
    334,429
    29,306,0134.51
    Alexion Pharmaceuticals Inc
    ALXN US
    216,018
    28,229,2324.35
    Top 10 Total (%)72.99
    These are not recommendations to buy or to sell any security. Securities and holdings may vary.
  • Country Weightings (%) as of 01/31/17

    • Country

      % of Net Assets
    • UNITED STATES

      98.05
    • SPAIN

      1.86
    • Other/Cash

      0.09
  • Sector Weightings (%) as of 01/31/17

    • Sector

      % of Net Assets
    • Health Care

      99.9
    • Other/Cash

      0.1